Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility
Genor obtained marketing approval for its first product in China, one more is expected this year. Commercial execution remains the key near-term...
630 Views
Genor Biopharma (6998.HK) - Here Is Why the Stock Price Decreased by About 50%
This article analyzed the concerns of Genor Biopharma in terms of core products, competitive landscape, industry characteristics and the potential...
422 Views
What HKEX Biotech "Step-Ups" Can Tell Us
This Insight explains the concept of valuation "step-ups" for pre-revenue biotechnology companies listing on the HKEX and how to use this data to...
507 Views
JHBP Holdings (Genor Biopharma) IPO Initiation: Hunting for a Cure
$ Genor Biopharma is a biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. Its drug candidates...
530 Views
HK IPO Analytics 1H2019: MS and CICC Stand Out
At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...
792 Views